Refractory Case of ALK-Negative Anaplastic Large-Cell Lymphoma with PAX-5 Expression and T-Cell Receptor-γ Gene Rearrangement
スポンサーリンク
概要
著者
-
Murata Tetsuya
Division Of Pathology And Clinical Laboratories Suzuka General Hospital
-
Baba Yohichiro
Division Of Pathology And Clinical Laboratories Suzuka General Hospital
-
Kawakami Keiki
Division Of Hematology And Oncology Suzuka General Hospital
-
Imai Hiroshi
Pathology Division Mie University Hospital
-
YAZAKI Akira
Division of Hematology/Oncology, Suzuka General Hospital
-
ITO Ryugo
Division of Hematology/Oncology, Suzuka General Hospital
-
TONO Yasutaka
Division of Hematology/Oncology, Suzuka General Hospital
-
UCHIYAMA Tomoko
Division of Pathology and Clinical Laboratories, Suzuka General Hospital
-
NAKAMURA Shigeo
Department of Applied Chemistry, Faculty of Engineering, Kanagawa University
-
Imai Hiroshi
Pathology Division, Mie University Hospital
関連論文
- Determination of Total Hydroperoxides in Oxidized Vegetable Oils Based on Triphenylphosphine Oxidation Using Electron Ionization Mass Spectrometry
- Increased Expression of Sucrase and Intestinal-type Alkaline Phosphatase in Human Gastric Carcinomas with Progression
- Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma
- Castleman's Disease of the Retroperitoneum : With Special Reference to IgG4-Related Disorder
- A case of acute myeloblastic leukemia with a novel variant of t(8;21)(q22;q22)
- Biological safety of water-soluble fullerenes evaluated using tests for genotoxicity, phototoxicity, and pro-oxidant activity
- A Case of Acute Myeloid Leukemia with t(7;11)(p15;p15) Mimicking Myeloid Crisis of Chronic Myelogenous Leukemia
- Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma
- Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas : Results of a Japanese Phase II Study
- Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma